Covered recipient · General Payments record
ANJAY RASTOGI
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$337,065.29
425 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $196,668.26 | 63 |
| Travel and Lodging | $56,801.44 | 156 |
| Consulting Fee | $54,989.79 | 19 |
| Honoraria | $17,000.00 | 9 |
| Food and Beverage | $11,605.80 | 178 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $95,899.07 | 118 |
| Vifor Pharma, Inc. | $93,796.88 | 105 |
| AstraZeneca Pharmaceuticals LP | $59,787.57 | 71 |
| Fresenius USA Marketing, Inc. | $37,471.63 | 53 |
| AKEBIA THERAPEUTICS INC | $10,200.00 | 1 |
| Baxter Healthcare | $9,884.69 | 22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $9,023.27 | 9 |
| GENZYME CORPORATION | $6,170.20 | 10 |
| Travere Therapeutics, Inc. | $4,557.22 | 9 |
| Aurinia Pharma U.S., Inc. | $3,647.79 | 4 |
| Amgen Inc. | $3,427.05 | 6 |
| GlaxoSmithKline, LLC. | $1,787.50 | 1 |
| Chiesi USA, Inc. | $455.32 | 3 |
| Amicus Therapeutics, Inc. | $338.30 | 6 |
| Novo Nordisk Inc | $220.00 | 1 |
| Alexion Pharmaceuticals, Inc. | $156.39 | 2 |
| Horizon Therapeutics plc | $92.65 | 1 |
| SANOFI-AVENTIS U.S. LLC | $86.77 | 1 |
| Ablative Solutions, Inc. | $39.04 | 1 |
| CALLIDITAS THERAPEUTICS US INC. | $23.95 | 1 |
Page 7 of 9; records 301–350 of 425 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANJAY RASTOGI
NPI 1003836602 · CMS profile ID 160
Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
LOS ANGELES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 7 of 9; records 301–350 of 425 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1003836602?year=2022&recipient=provider&page=7#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANJAY RASTOGI, NPI 1003836602, CMS profile ID 160. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 9; records 301–350 of 425 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003836602?year=2022&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). ANJAY RASTOGI, NPI 1003836602, CMS profile ID 160. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 9; records 301–350 of 425 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003836602?year=2022&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- ANJAY RASTOGI, NPI 1003836602, CMS profile ID 160, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 9; records 301–350 of 425 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1003836602?year=2022&recipient=provider&page=7#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
425 matching records · $337,065.29 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 301–350 of 425.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $4,440.00 | 03/21/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930016311 | CMS |
| Ablative Solutions, Inc. | $39.04 | 03/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942022563 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $272.83 | 03/17/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929994795 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $100.00 | 03/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930135331 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $108.69 | 03/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930003105 | CMS |
| Vifor Pharma, Inc. | $36.75 | 03/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 896740145 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $6.39 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929862839 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $7.41 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929863437 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $120.00 | 03/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929957965 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $22.73 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929978117 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $120.00 | 03/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929980875 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $61.16 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930008293 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $120.00 | 03/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930008305 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $15.01 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930017871 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $120.00 | 03/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930033495 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $14.51 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930116225 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $5,550.00 | 03/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930122383 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $3,885.00 | 03/10/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930133515 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $120.00 | 03/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930140155 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $25.00 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930178169 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $14.71 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930185343 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.90 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930189209 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $120.00 | 03/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930308063 | CMS |
| Vifor Pharma, Inc. | $35.23 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 896740139 | CMS |
| Vifor Pharma, Inc. | $35.23 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 896740141 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $1,570.97 | 03/05/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930111513 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $531.26 | 03/05/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930140403 | CMS |
| Fresenius USA Marketing, Inc. | $7.92 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954550669 | CMS |
| Fresenius USA Marketing, Inc. | $121.11 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954550767 | CMS |
| Fresenius USA Marketing, Inc. | $171.60 | 03/03/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954550803 | CMS |
| Fresenius USA Marketing, Inc. | $502.60 | 03/03/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954567011 | CMS |
| Fresenius USA Marketing, Inc. | $1,221.90 | 03/03/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954567083 | CMS |
| Fresenius USA Marketing, Inc. | $2,500.00 | 03/03/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954567117 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,500.00 | 03/02/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914908715 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $5.04 | 03/02/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929882205 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $208.99 | 03/02/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929994791 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $15.00 | 03/02/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930189213 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,000.00 | 03/01/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915055045 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $125.00 | 03/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930106289 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $493.95 | 03/01/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930281353 | CMS |
| AstraZeneca Pharmaceuticals LP | $197.80 | 02/28/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915023911 | CMS |
| AstraZeneca Pharmaceuticals LP | $153.88 | 02/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915060995 | CMS |
| AstraZeneca Pharmaceuticals LP | $38.00 | 02/28/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915254943 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.30 | 02/28/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915418069 | CMS |
| AstraZeneca Pharmaceuticals LP | $240.00 | 02/28/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915565241 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $802.25 | 02/27/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930232135 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $167.18 | 02/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930262835 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $118.00 | 02/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930144951 | CMS |
| Fresenius USA Marketing, Inc. | $81.24 | 02/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954550725 | CMS |
| Fresenius USA Marketing, Inc. | $214.50 | 02/23/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954550809 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $10,471.25 | 2 |
| PY2025 | Principal investigator | $153,970.40 | 25 |
| PY2024 | Principal investigator | $723,946.24 | 24 |
| PY2023 | Principal investigator | $207,737.80 | 16 |
| PY2022 | Principal investigator | $353,966.14 | 40 |
| PY2021 | Principal investigator | $458,915.15 | 51 |
| PY2020 | Recipient | $11,262.55 | 1 |
| PY2020 | Principal investigator | $766,044.51 | 122 |
| PY2019 | Recipient | $934.24 | 11 |
| PY2019 | Principal investigator | $1,475,303.92 | 58 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
27 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GENZYME CORPORATION | $10,055.00 | 12/08/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226142633 |
| Principal investigator 1 | GENZYME CORPORATION | $3,692.00 | 10/20/2025 | Non-covered Recipient Entity New York Medical College Office Of Research Administration Skyline Rm J23 | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226155810 |
| Recipient | Novartis Pharmaceuticals Corporation | $4,337.00 | 10/20/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190293286 |
| Principal investigator 1 | GENZYME CORPORATION | $500.00 | 10/14/2025 | Non-covered Recipient Entity New York Medical College Office Of Research Administration Skyline Rm J23 | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226155806 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $1,038.69 | 10/01/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants | No dispute reported | 06/30/2026 | 1214125080 |
| Principal investigator 1 | GENZYME CORPORATION | $1,000.00 | 09/29/2025 | Non-covered Recipient Entity New York Medical College Office Of Research Administration Skyline Rm J23 | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226155800 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,332.89 | 09/25/2025 | Non-covered Recipient Entity The Regents Of The Univ Of California | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K | No dispute reported | 06/30/2026 | 1225414736 |
| Principal investigator 1 | GENZYME CORPORATION | $3,726.00 | 09/22/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226142563 |
| Principal investigator 1 | GENZYME CORPORATION | $4,851.00 | 09/22/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226142568 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $64,771.28 | 08/26/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Study to Determine the Prevalence, Demographic, and Clinical Characteristics Associated With PKD1 Variant Groups in Individuals Diagnosed With ADPKD | No dispute reported | 06/30/2026 | 1214124212 |
| Principal investigator 1 | GENZYME CORPORATION | $2,368.60 | 08/25/2025 | Non-covered Recipient Entity New York Medical College Office Of Research Administration Skyline Rm J23 | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226155796 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $283.50 | 07/24/2025 | Non-covered Recipient Entity The Regents Of The Univ Of California | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K | No dispute reported | 06/30/2026 | 1225413336 |
| Principal investigator 1 | GENZYME CORPORATION | $1,000.00 | 07/07/2025 | Non-covered Recipient Entity New York Medical College Office Of Research Administration Skyline Rm J23 | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226156185 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $283.50 | 07/03/2025 | Non-covered Recipient Entity The Regents Of The Univ Of California | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K | No dispute reported | 06/30/2026 | 1225413264 |
| Principal investigator 1 | GENZYME CORPORATION | $7,142.00 | 06/09/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226142524 |
| Principal investigator 1 | GENZYME CORPORATION | $24,328.00 | 06/09/2025 | Non-covered Recipient Entity New York Medical College Office Of Research Administration Skyline Rm J23 | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226156111 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,816.29 | 05/30/2025 | Non-covered Recipient Entity The Regents Of The Univ Of California | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K | No dispute reported | 06/30/2026 | 1225412772 |
| Recipient | Novartis Pharmaceuticals Corporation | $6,134.25 | 05/21/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190293290 |
| Principal investigator 1 | GENZYME CORPORATION | $750.00 | 05/05/2025 | Non-covered Recipient Entity New York Medical College Office Of Research Administration Skyline Rm J23 | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226156090 |
| Principal investigator 1 | GENZYME CORPORATION | $5,546.00 | 04/28/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226142502 |
| Principal investigator 1 | GENZYME CORPORATION | $4,686.00 | 03/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226142482 |
| Principal investigator 1 | GENZYME CORPORATION | $4,802.20 | 03/17/2025 | Non-covered Recipient Entity New York Medical College Office Of Research Administration Skyline Rm J23 | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226156025 |
| Principal investigator 1 | GENZYME CORPORATION | $750.00 | 03/17/2025 | Non-covered Recipient Entity New York Medical College Office Of Research Administration Skyline Rm J23 | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226156031 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,772.19 | 03/06/2025 | Non-covered Recipient Entity The Regents Of The Univ Of California | BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic | No dispute reported | 06/30/2026 | 1225404840 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,448.00 | 02/04/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients | No dispute reported | 06/30/2026 | 1190293375 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $184.26 | 01/09/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA AT LOS ANGELES | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients | No dispute reported | 06/30/2026 | 1190302553 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $3,843.00 | 01/07/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease | No dispute reported | 06/30/2026 | 1214124210 |